Click here
to view this message in a web browser
 |
||
| Value-Based Payment Models in Oncology: Deloitte Research on Impact of New Payment Models | ||
|
The costs of treating cancer are rising -
approximately $124.6 billion in 2010 in the United States and projected
to grow to $158 billion to $173 billion by 2020.
Today, many health plans, health systems, and oncology groups have begun
experimenting with value-based payment models to control rising costs,
reduce unexplained variation in care, and improve patient outcomes. Four
value-based payment models are being tested in the commercial market:
(1) Financial incentives for adhering to clinical pathways; (2)
Patient-centered medical homes (PCMHs); (3) Bundled payments; and (4)
Specialty accountable care organizations (ACOs). In addition, CMS
recently launched the Oncology Care Model (OCM), a 2-part payment
system, resembling a PCMH and a bundled payment model. Many of these
models target drug spending. The Deloitte Center for Health Solutions recently interviewed stakeholders from health plans, provider groups, and clinical pathway developers that are participating, supporting, or evaluating oncology payment models to understand what approaches are perceived to be working, and what the early results (financial and clinical) have been. They also sought to understand how these payment models affect the use of new treatments. With rapid advances in diagnostics, precision medicine, and immunotherapy, how can a standardized payment model be defined that leaves room for innovation? Deloitte research reveals that many organizations are experimenting with value- based payment models that aim to balance the competing goals of controlling costs and allowing access to advances in treatment. While none of the participating organizations claimed to have solved this equation, all of them indicated that they had seen early signs of success and were working to evolve and expand these models. Please join us Wednesday, May 31st 2017 at 12 PM Eastern as Deloitte's Sonal Shah, PharmD and Bushra Naaz explain Deloitte's insights and research findings. Click here for detailed information and to register or call 209.577.4888. |
||
 |
||
|
healthexecwire |